Abstract: Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.
Type:
Application
Filed:
November 29, 2018
Publication date:
June 20, 2019
Applicant:
Seattle Genetics, Inc.
Inventors:
Shyra Gardai, Matthew Levengood, Vivian Trang, Lori Westendorf, Christopher Carosino, Che Leung-Law, Michael Feldhaus
Abstract: Compounds and compositions are disclosed in which a Drug Unit is linked to a targeting Ligand Unit through a self-stabilizing Linker Unit from which a drug compound or active drug moiety is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.
Abstract: The invention provides methods of treating a subject having or at risk of cancer by administering a LIV-1 antibody drug conjugate and a chemotherapeutic.
Abstract: This invention relates to treatment of cancer using antibody drug conjugates that comprise PBD molecules in combination with Bcl-2 inhibitors.
Type:
Application
Filed:
March 15, 2017
Publication date:
March 14, 2019
Applicant:
SEATTLE GENETICS, INC.
Inventors:
William Arthur, Robert Thurman, Travis Biechele, Rory Rohm
Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
Type:
Grant
Filed:
January 27, 2016
Date of Patent:
February 12, 2019
Assignee:
SEATTLE GENETICS, INC.
Inventors:
Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
Type:
Application
Filed:
October 3, 2018
Publication date:
January 24, 2019
Applicant:
SEATTLE GENETICS, INC.
Inventors:
Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
Abstract: Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.
Abstract: Disclosed are formulations, including both liquid and lyophilized formulations, comprising a benzodiazepine antibody-drug conjugate (ADC) and a cyclodextrin. Also disclosed are methods of purifying mixtures comprising benzodiazepine antibody-drug conjugates and process drug-related impurities.
Type:
Application
Filed:
April 30, 2018
Publication date:
December 27, 2018
Applicant:
SEATTLE GENETICS, INC.
Inventors:
Hui Li, Shan Jiang, Mary Wallace, Damon Meyer
Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an effective amount of 2-deoxy-2-fluoro-L-fucose or a prodrug thereof, or a pharmaceutically acceptable salt thereof, in combination with a checkpoint inhibitor.
Type:
Application
Filed:
December 2, 2016
Publication date:
December 13, 2018
Applicant:
SEATTLE GENETICS, INC.
Inventors:
Shyra Gardai, Che-Leung Law, Peter Senter, Nicole Okeley, Jessica Field
Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
Abstract: Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells, such as multiple myeloma, non-Hodgkin lymphoma and acute myeloid leukemia.
Type:
Application
Filed:
June 30, 2016
Publication date:
June 21, 2018
Applicant:
SEATTLE GENETICS, INC.
Inventors:
Timothy Lewis, Lori Westendorf, Django Sussman, Che-Leung Law
Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.
Abstract: Disclosed are formulations, including both liquid and lyophilized formulations, comprising a benzodiazepine antibody-drug conjugate (ADC) and a cyclodextrin. Also disclosed are methods of purifying mixtures comprising benzodiazepine antibody-drug conjugates and process drug-related impurities.
Type:
Grant
Filed:
March 9, 2017
Date of Patent:
June 5, 2018
Assignee:
Seattle Genetics, Inc.
Inventors:
Hui Li, Shan Jiang, Mary Wallace, Damon Meyer
Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
Type:
Grant
Filed:
March 14, 2016
Date of Patent:
May 8, 2018
Assignees:
AGENSYS, INC., SEATTLE GENETICS, INC.
Inventors:
Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
Abstract: The present invention provides methods and systems for the rapid determination of the intact mass of non-covalently associated antibody heavy chains (HC) and light chains (LC) which result from the attachment of drug conjugates to interchain cysteine residues. By analyzing the antibody-drug conjugate (ADC) using native desalting conditions, the intact-bivalent structure of the ADC, which ordinarily would decompose as a consequence of denaturing chromatographic conditions typically used for LCMS, is maintained. The mass of the desalted ADC is subsequently determined using desolvation and ionization ESI-MS conditions. The methods described herein provide for direct measurement of the intact mass of an ADC conjugated at interchain cysteine residues. The methods described herein also provide for the relative quantitation of the individual ADC species.
Type:
Grant
Filed:
September 27, 2012
Date of Patent:
May 1, 2018
Assignee:
Seattle Genetics, Inc.
Inventors:
John Fay Valliere-Douglass, Oscar Salas
Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
Type:
Grant
Filed:
March 2, 2017
Date of Patent:
October 30, 2018
Assignees:
AGENSYS, INC., SEATTLE GENETICS, INC.
Inventors:
Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia